Pterygia are indicators of an increased risk of developing cutaneous melanomas

Julie M Crewe, Tim Threlfall, Antony Clark, Paul G. Sanfilippo, David A. Mackey

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

AIM: To investigate whether pterygium is an indicator of an increased risk of cutaneous melanoma (CM).

METHODS: A matched-cohort study, using linked health administrative data sets to identify all hospital-treated pterygium in Western Australia (WA) between 1979 and 2014. We identified pterygium cases from hospital diagnosis and/or procedure International Classification of Diseases 9th revision (ICD-9) and 10th revision (ICD-10) codes and matched cases by age, sex and residential postcode to WA Electoral Roll controls with no known history of pterygium. Both cohorts were linked to the WA Cancer Registry and the WA Deaths Registry.

RESULTS: 23 625 people had pterygium treatment (64% male) in WA hospitals. The median age for pterygium diagnosis and/or treatment was 49 years (range 14-96). There were significantly more CM cases in the pterygium cohort compared with the control cohort (1083 vs 874; p<0.001). In a logistic regression analysis, there was a 24% increase in the odds of developing a CM in the pterygium cohort, compared with controls, after controlling for other predictors (OR 1.24, 95% CI 1.1 to 1.4). The incident rate ratio (IRR) of a malignant CM diagnosis was 20% greater in people who had treatment for a pterygium compared with controls (IRR 1.2, 95% CI 1.0 to 1.4).

CONCLUSION: The presence of a pterygium indicates a significantly increased risk of developing a CM. Eye care providers who see patients with developing pterygia should advise these patients of this increased risk and recommend regular skin surveillance.

Original languageEnglish
JournalBritish Journal of Opthalmology
DOIs
Publication statusPublished - 2018

Fingerprint

Pterygium
Melanoma
Skin
Western Australia
Registries
International Classification of Diseases
Cohort Studies
Therapeutics
Logistic Models
Regression Analysis

Cite this

@article{f6546cc658a34eeabc13322e6d37c6ae,
title = "Pterygia are indicators of an increased risk of developing cutaneous melanomas",
abstract = "AIM: To investigate whether pterygium is an indicator of an increased risk of cutaneous melanoma (CM).METHODS: A matched-cohort study, using linked health administrative data sets to identify all hospital-treated pterygium in Western Australia (WA) between 1979 and 2014. We identified pterygium cases from hospital diagnosis and/or procedure International Classification of Diseases 9th revision (ICD-9) and 10th revision (ICD-10) codes and matched cases by age, sex and residential postcode to WA Electoral Roll controls with no known history of pterygium. Both cohorts were linked to the WA Cancer Registry and the WA Deaths Registry.RESULTS: 23 625 people had pterygium treatment (64{\%} male) in WA hospitals. The median age for pterygium diagnosis and/or treatment was 49 years (range 14-96). There were significantly more CM cases in the pterygium cohort compared with the control cohort (1083 vs 874; p<0.001). In a logistic regression analysis, there was a 24{\%} increase in the odds of developing a CM in the pterygium cohort, compared with controls, after controlling for other predictors (OR 1.24, 95{\%} CI 1.1 to 1.4). The incident rate ratio (IRR) of a malignant CM diagnosis was 20{\%} greater in people who had treatment for a pterygium compared with controls (IRR 1.2, 95{\%} CI 1.0 to 1.4).CONCLUSION: The presence of a pterygium indicates a significantly increased risk of developing a CM. Eye care providers who see patients with developing pterygia should advise these patients of this increased risk and recommend regular skin surveillance.",
author = "Crewe, {Julie M} and Tim Threlfall and Antony Clark and Sanfilippo, {Paul G.} and Mackey, {David A.}",
note = "{\circledC} Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.",
year = "2018",
doi = "10.1136/bjophthalmol-2017-310686",
language = "English",
journal = "British Journal of Opthalmology",
issn = "0007-1161",
publisher = "BRITISH MED JOURNAL PUBL GROUP",

}

TY - JOUR

T1 - Pterygia are indicators of an increased risk of developing cutaneous melanomas

AU - Crewe, Julie M

AU - Threlfall, Tim

AU - Clark, Antony

AU - Sanfilippo, Paul G.

AU - Mackey, David A.

N1 - © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

PY - 2018

Y1 - 2018

N2 - AIM: To investigate whether pterygium is an indicator of an increased risk of cutaneous melanoma (CM).METHODS: A matched-cohort study, using linked health administrative data sets to identify all hospital-treated pterygium in Western Australia (WA) between 1979 and 2014. We identified pterygium cases from hospital diagnosis and/or procedure International Classification of Diseases 9th revision (ICD-9) and 10th revision (ICD-10) codes and matched cases by age, sex and residential postcode to WA Electoral Roll controls with no known history of pterygium. Both cohorts were linked to the WA Cancer Registry and the WA Deaths Registry.RESULTS: 23 625 people had pterygium treatment (64% male) in WA hospitals. The median age for pterygium diagnosis and/or treatment was 49 years (range 14-96). There were significantly more CM cases in the pterygium cohort compared with the control cohort (1083 vs 874; p<0.001). In a logistic regression analysis, there was a 24% increase in the odds of developing a CM in the pterygium cohort, compared with controls, after controlling for other predictors (OR 1.24, 95% CI 1.1 to 1.4). The incident rate ratio (IRR) of a malignant CM diagnosis was 20% greater in people who had treatment for a pterygium compared with controls (IRR 1.2, 95% CI 1.0 to 1.4).CONCLUSION: The presence of a pterygium indicates a significantly increased risk of developing a CM. Eye care providers who see patients with developing pterygia should advise these patients of this increased risk and recommend regular skin surveillance.

AB - AIM: To investigate whether pterygium is an indicator of an increased risk of cutaneous melanoma (CM).METHODS: A matched-cohort study, using linked health administrative data sets to identify all hospital-treated pterygium in Western Australia (WA) between 1979 and 2014. We identified pterygium cases from hospital diagnosis and/or procedure International Classification of Diseases 9th revision (ICD-9) and 10th revision (ICD-10) codes and matched cases by age, sex and residential postcode to WA Electoral Roll controls with no known history of pterygium. Both cohorts were linked to the WA Cancer Registry and the WA Deaths Registry.RESULTS: 23 625 people had pterygium treatment (64% male) in WA hospitals. The median age for pterygium diagnosis and/or treatment was 49 years (range 14-96). There were significantly more CM cases in the pterygium cohort compared with the control cohort (1083 vs 874; p<0.001). In a logistic regression analysis, there was a 24% increase in the odds of developing a CM in the pterygium cohort, compared with controls, after controlling for other predictors (OR 1.24, 95% CI 1.1 to 1.4). The incident rate ratio (IRR) of a malignant CM diagnosis was 20% greater in people who had treatment for a pterygium compared with controls (IRR 1.2, 95% CI 1.0 to 1.4).CONCLUSION: The presence of a pterygium indicates a significantly increased risk of developing a CM. Eye care providers who see patients with developing pterygia should advise these patients of this increased risk and recommend regular skin surveillance.

U2 - 10.1136/bjophthalmol-2017-310686

DO - 10.1136/bjophthalmol-2017-310686

M3 - Article

JO - British Journal of Opthalmology

JF - British Journal of Opthalmology

SN - 0007-1161

ER -